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“Happy	  families	  are	  all	  alike;	  every	  
unhappy	  family	  is	  unhappy	  in	  its	  
own	  way.”	  
	  Leo	  Tolstoy,	  Anna	  Karenina,	  Chapter	  
1,	  ﬁrst	  line	  
Russian	  mys6c	  &	  novelist	  (1828	  -­‐	  
1910)	  	  
*Quote	  introduced	  to	  gene6cs	  community	  by	  Mary-­‐Claire	  King	  
“We	  don’t	  have	  to	  look	  for	  a	  model	  
organism	  anymore,	  because	  we	  are	  
the	  model	  organisms.”	  
	  
–	  Sydney	  Brenner,	  Nobel	  Laureate,	  
quote	  in	  2008	  
Hypothesis: Every	  human	  is	  a	  
unique	  gene6c	  organism.	  
Therefore,	  we	  can	  ﬁnd	  previously	  
unreported	  idiopathic	  disorders	  in	  
humans	  and	  iden6fy	  their	  gene6c	  
basis,	  thus	  revealing	  substan6al	  
new	  biology	  relevant	  to	  medicine.	  	  
	  

I	  moved	  to	  Utah	  July	  2009	  to	  ﬁnd	  new	  rare	  
diseases	  AND	  to	  study	  disease	  in	  large	  pedigrees,	  
controlling	  for	  environment	  and	  populaCon	  
eﬀects.	  
	  
  July	  2009-­‐December	  2009:	  AIended	  weekly	  geneCcs	  
case	  conference	  in	  which	  10-­‐30	  geneCc	  cases	  are	  
presented	  weekly,	  led	  by	  Dr.	  Alan	  Rope	  and	  aIended	  
by	  Drs.	  John	  Carey	  and	  John	  Opitz.	  
	  
  There	  are	  indeed	  MANY	  idiopathic	  “Mendelian”	  
disorders	  not	  described	  in	  the	  literature	  and	  NOT	  in	  
OMIM,	  many	  of	  which	  have	  neuropsychiatric	  
manifestaCons.	  
Story	  #1	  
American	  Journal	  of	  Human	  Gene6cs	  89,	  28-­‐43	  (2011).	  	  
“liale	  old	  man”,	  prominence	  of	  eyes,	  down-­‐sloping	  palpebral	  ﬁssures,	  
thickened	  eyelids,	  large	  ears,	  beaking	  of	  nose,	  ﬂared	  nares,	  
hypoplas6c	  nasal	  alae,	  short	  columella,	  protruding	  upper	  lip,	  micro-­‐
retrognathia	  
	  
Finding a new disease and figuring out its genetic basis 
I	  met	  the	  enCre	  family	  on	  March	  29,	  2010,	  
collecCng	  all	  blood	  for	  DNA	  and	  cell	  lines.	  
Photo	  of	  mother,	  now	  a	  
grandmother,	  
with	  son	  in	  late	  1970’s	  
*Picture	  NOT	  for	  public	  distribu6on.	  
First	  boy.	  Called	  “a	  liale	  old	  man”	  by	  
the	  family.	  Died	  around	  ~1	  year	  of	  
age,	  from	  cardiac	  arrhythmias.	  
This	  is	  the	  ﬁrst	  boy	  in	  the	  late	  1970’s.	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This	  is	  the	  family	  in	  Utah	  in	  March	  2010.	  
These	  are	  the	  Major	  Features	  of	  the	  Syndrome.	  
Remarkably,	  for	  the	  most	  part,	  gross	  inspecCon	  at	  
autopsy	  and	  histopathology	  were	  unremarkable	  for	  
clues	  explaining	  the	  pathogenesis	  of	  this	  condiCon,	  
other	  than	  cardiac	  failure.	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Experimental Design for Sequencing is Critical. 
  X-­‐chromosome	  exon	  capture	  with	  Agilent,	  
followed	  by	  Next	  Gen	  Sequencing	  with	  
Illumina.	  
  Analysis	  with	  ANNOVAR	  and	  VAAST	  (Variant	  
AnnotaCon,	  Analysis	  and	  Search	  Tool).	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Analysis	  with	  VAAST	  readily	  idenCﬁed	  a	  
few	  likely	  candidates.	  
Mutation 
WT 









This is the causative mutation. There are ~6 billion 
nucleotide in a diploid human genome, but this one 
REALLY matters! 
 The	  discovery	  (or	  “Eureka	  moment”)	  occurred	  when	  
blinded	  Sanger	  sequencing	  showed	  perfect	  segregaCon	  of	  
one	  mutaCon	  with	  the	  disease.	  
 MutaCon	  present	  in	  Proband,	  Carrier	  Mother,	  Carrier	  
Grandmother	  and	  other	  carrier	  mothers.	  
 Absent	  in	  unaﬀected	  brother	  and	  unaﬀected	  uncle.	  
 Also	  present	  in	  DNA	  from	  formalin-­‐ﬁxed	  paraﬃn-­‐
embedded	  Cssue	  from	  two	  other	  deceased	  boys,	  found	  in	  
pathology	  department,	  saved	  in	  one	  case	  for	  30	  years.	  
A	  Second	  Family	  was	  Iden6ﬁed	  with	  Same	  
Muta6on,	  Despite	  the	  Fact	  that	  the	  Two	  
Families	  do	  NOT	  share	  a	  common	  founder.	  
II-1 III-2 
Contributed	  by	  Les	  Biesecker	  and	  colleagues	  at	  NIH	  
The	  N-­‐terminal	  acetylaCon	  machinery	  
in	  human	  cells.	  	  
Slide	  courtesy	  of	  Thomas	  Arnesen	  
The human N-Acetylome 
•  A majority of soluble human proteins are N-terminally acetylated 
•  NatA is a major protein modifying enzyme of the human proteome   




















	  	  	  	  	  	  	  NatE	  
	  	  	  	  	  	  NatF	  	  	  	  
NAT	  acCvity	  of	  recombinant	  hNaa10p	  
WT	  or	  p.Ser37Pro	  towards	  syntheCc	  
N-­‐terminal	  pepCdes.	  	  
	  hNaa10p-­‐S37P	  is	  funcConally	  
impaired	  in	  vivo	  using	  a	  yeast	  model.	  
	  
Unpublished,	  ﬁgure	  courtesy	  of	  Thomas	  Arnesen	  
By	  November	  2010,	  we	  had	  good	  
func6onal	  data	  in	  vitro	  (bacterially	  
expressed	  proteins)	  and	  in	  vivo	  (yeast,	  
unpublished),	  leading	  me	  to	  believe	  
we	  had	  iden6ﬁed	  the	  causa6ve	  
muta6on.	  
	  
A	  new	  mother	  in	  the	  family	  informs	  me	  
she	  is	  4	  months	  pregnant,	  with	  a	  boy!	  
The	  now	  pregnant	  mother-­‐to-­‐be	  is	  circled	  in	  red.	  
Our	  Sanger	  Sequencing	  had	  shown	  her	  to	  be	  a	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BUT,	  how	  do	  we	  give	  such	  research	  results	  back	  to	  
paCents?	  
	  
HippocraCc	  Oath:	  FIRST	  DO	  NO	  HARM.	  
MAJOR	  ISSUES	  
 I	  am	  a	  physician	  but	  not	  HER	  physician,	  therefore	  I	  had	  NOT	  
entered	  into	  a	  “physician-­‐pa6ent	  contract”	  with	  her.	  
 This	  was	  not	  a	  “diagnos6c	  test”.	  This	  was	  research.	  
 The	  IRB	  protocol	  dictated	  that	  research	  results	  cannot	  be	  
returned	  to	  these	  research	  subjects.	  
 There	  are,	  of	  course,	  MANY	  reasons	  for	  why	  all	  of	  this	  IS	  the	  
way	  that	  it	  IS….	  Discussed	  at	  length	  by	  prior	  speakers	  at	  this	  
mee6ng.	  
 So,	  I	  did	  NOT	  return	  the	  results	  to	  the	  mother	  to	  be.	  
Mother	  four	  months	  	  
Pregnant	  Nov	  2010	  
	  
Baby	  born	  March	  2011.	  
	  
Aﬀected	  with	  Disease.	  
	  
He	  died	  June	  2011,	  
same	  week	  as	  
publicaCon	  of	  our	  
paper	  in	  AJHG.	  
	  
We	  did	  develop	  a	  CLIA-­‐
cerCﬁed	  test	  for	  the	  
future.	  
*Picture	  NOT	  for	  public	  distribu6on.	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Ogden Syndrome, in honor of where the first family 
lives, in Ogden, Utah 
Story	  #2	  –	  Psychiatric	  GeneCcs	  is	  MUCH	  harder!	  
I	  am	  very	  supporCve	  of	  open-­‐access	  publishing!	  
This	  is	  the	  ADHD	  pedigree	  in	  January	  
2010,	  admiaedly	  small	  but	  very	  well	  
phenotyped	  for	  four	  members.	  
Figure 1. The pedigree structure is shown, with corresponding ID 
numbers. The three subjects in the pedigree affected with ADHD are 
shaded. Only 84060 has the idiopathic hemolytic anemia. The mother, 
father and two sons were sequenced. The two sisters in the family 
declined to participate in the study, thus their phenotype status is 
unknown and marked as “?”. 
	

Figure 1. The pedigree structure is shown, with corresponding ID 
numbers. The three subjects in the pedigree affected with ADHD are 
shaded. Only 84060 has the idiopathic hemolytic anemia. The mother, 
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Supplementary Table 1. ADHD measures during a clinical trial of methylphenidate 
transdermal system. 
    92157 84060 84615 
Baseline    
 WRAADDS 16 22 16 
 ODD 1 11 7 
 CAARS 40 55 38 
 CGI-S 4 4 4 
Active Medication    
 WRAADDS 0 4 3 
 ODD 0 1 3 
 CAARS 10 0 13 
 CGI-I 1 1 1 
 CGI-S 1 3 2 
Placebo     
 WRAADDS 15 24 20 
 ODD 6 8 7 
 CAARS 33 51 42 
 CGI-I 4 4 N/A 
 CGI-S 4 5 N/A 
 
 
WRAADDS: Total score on the Wender Reimherr Adult ADD Scale  
ODD: Oppositional Defiant Disorder scaore on the WRAADDS ODD subscale 
CAARS: Total score Connor’s Adult ADHD Rating Scale 
CGI-S: Clinical Global Impression, Severity score.  
!
Phenotyping	  is	  CriCcally	  Important	  in	  Neuropsychiatric	  Disorders!	  
Exome	  Sequencing	  performed	  early	  
2010	  
While	  analyzing	  the	  exome	  data,	  research	  subject	  
(age	  ~24)	  informs	  me	  that	  he	  recently	  had	  his	  spleen	  
removed!	  
	  
He	  has	  idiopathic	  hemolyCc	  anemia,	  since	  
childhood….	  
	  
Although	  I	  am	  not	  his	  physician,	  I	  sCll	  feel	  an	  ethical	  
and	  moral	  obligaCon	  to	  try	  to	  ﬁgure	  out	  what	  is	  
going	  on….	  
This	  was	  our	  ﬁltering	  pipeline.	  
!
Compound	  Heterozygote	  in	  PKLR,	  with	  
each	  muta6on	  inherited	  from	  one	  
parent.	  
!
Some	  Addi6onal	  Data	  to	  support	  the	  
causa6on	  of	  these	  variants	  for	  
idiopathic	  hemoly6c	  anemia.	  
Structural	  Modeling	  is	  also	  consistent	  with	  deleterious	  eﬀects	  of	  these	  muta6ons.	  
 In	  our	  case,	  we	  communicated	  the	  research	  results	  
back	  to	  the	  hematologist,	  asking	  the	  doctor	  to	  follow	  
up	  with	  appropriate	  geneCc	  tests	  and	  counseling.	  
 There	  is	  NOTHING	  “Incidental”	  about	  Unrelated	  
Findings.	  
 Sequencing	  a	  bunch	  of	  exomes	  and	  ﬁnding	  random	  
rare	  variants	  MIGHT	  be	  “incidental”,	  but	  actually	  
proving	  that	  these	  variants	  CAUSE	  the	  disease	  is	  NOT	  
simple	  or	  “incidental”	  or	  “accidental”.	  	  
 I	  would	  suggest	  calling	  these	  “unrelated	  ﬁndings”,	  
rather	  than	  “incidental”.	  
A	  Word	  on	  the	  IdenCﬁcaCon	  of	  Rare	  Variants	  
 We	  found	  many	  very	  rare	  variants	  segrega6ng	  with	  ADHD	  
in	  father	  and	  two	  sons,	  
 BUT	  we	  cannot	  prove	  with	  certainty	  that	  any	  of	  these	  
variants	  cause	  the	  disease,	  either	  by	  themselves	  or	  in	  
aggregate	  or	  with	  epista6c	  eﬀects.	  
 Biology	  experiments	  must	  be	  performed	  to	  further	  
bolster	  causality.	  	  
 Proving	  CAUSALITY	  for	  variants	  is	  criCcally	  important,	  as	  





 We	  have	  idenCﬁed	  a	  new,	  previously	  idiopathic,	  human	  
disorder	  likely	  resulCng	  from	  a	  defect	  in	  amino-­‐terminal	  
acetylaCon	  of	  proteins,	  opening	  the	  door	  to	  new	  biology	  with	  
this	  major	  protein	  modiﬁcaCon.	  
 We	  have	  used	  next	  generaCon	  sequencing	  to	  ﬁgure	  out	  the	  
geneCc	  basis	  of	  a	  case	  of	  idiopathic	  hemolyCc	  anemia,	  and	  
grappled	  with	  how	  to	  give	  back	  “unrelated	  ﬁndings”.	  
 The	  Cme	  is	  now	  to	  ﬁnd	  and	  study	  idiopathic	  diseases	  in	  
humans,	  using	  next	  generaCon	  sequencing.	  There	  are	  likely	  
MANY	  previously	  undescribed	  diseases.	  
	  
 I	  would	  suggest	  that	  researchers	  perform	  CLIA-­‐cerCﬁed	  
sequencing	  UP	  FRONT,	  either	  with	  exomes	  or	  whole	  genomes,	  
so	  that	  we	  can	  return	  results	  to	  research	  subjects,	  when	  and	  if	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Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
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The	  Exon	  Capture	  and	  Coverage	  was	  
high	  depth	  with	  Average	  Base	  
Coverage	  of	  214x,	  but…..	  
!
Table 2. Coverage Statistics in Family 1. Based on GNUMAP 



































* On chromosome X, there are 8,222 unique RefSeq exons. Of these exons, 736 were excluded from the SureSelect X-Chromosome Capture 
Kit because they were designated as pseudoautosomal or repetitive sequences (UCSC genome browser). 
Analysis	  with	  VAAST	  readily	  idenCﬁed	  
a	  few	  likely	  candidates.	  
Table 3. Summary of the filtering procedure and candidate genes using VAAST 
SNV$calling$pipeline$ GATK$$ Samtools$$ GNUMAP$$
III94$(total$SNVs)$ 1546$ 1499$ 2168$
III94$(nsSNVs)$ 146$ 114$ 155$
VAAST$candidate$genes$(NAA10$ranking)$ 4$(3)$ 3$(2)$ 5$(2)$
Present$in$III94$and$mother$II92$(nsSNVs)$ 122$ 107$ 116$
VAAST$candidate$genes$(NAA10$ranking)$ 3$(2)$ 2$(1)$ 2$(2)$
Present$in$III94,$mother$II92,$and$grandmother$I9
2$(nsSNVs)$ 115$ 95$ 104$
VAAST$candidate$genes$(NAA10$ranking)$ 2$(1)$ 2$(1)$ 1$(1)$
Present$in$III94,$II92,$and$I92,$absent$in$brother$
III92$and$uncle$II98$(nsSNVs)$ 8$ 6$ 8$
VAAST$candidate$genes$(NAA10$ranking)$ 1$(1)$ 1$(1)$ 2$(1)$
$
We	  analyzed	  the	  data	  with	  3	  pipelines.	  
Table 3: The SNV count, non-synonymous coding SNV count and Ti/Tv ratio for 
each individual for each variant analysis pipeline in Family 1. 
Sample Pipeline SNV Count Non-synonymous Ti/Tv 
III-4 
samtools 1499 114 2.0 
GATK 1546+236a 146+6 (nonsyn+frame) 2.0 
GNUMAP 2168  155  2.0 
II-2 
samtools 2512 219 1.6 
GATK 1999+270 a 168+8 2.1 
GNUMAP 2893  183   2.0 
III-2 
samtools 1491 106 2.0 
GATK 1509+252 a 134+10 2.0 
GNUMAP 2062  131  2.0 
I-2 
samtools 2637 229 1.5 
GATK 2032+278 a 160+10 2.0 
GNUMAP 2920  183   1.9 
II-8 
samtools 1513 108 1.9 
GATK 1572+243 a 136+8 1.9 
GNUMAP 1924  139  2.0 
amicroindels ascertained with GATK pipeline 
!
Structural	  modelling	  of	  hNaa10p	  wt	  
(cyan)	  and	  S37P	  (pink)	  	  	  
	  
The mutation causes Naa10p S37P. 
 








- Ser37Pro is predicted to affect functionality 
(SIFT-analysis) 
 
These	  two	  families	  are	  UNRELATED,	  i.e.	  
no	  common	  founder.	  
Courtesy	  of	  Chad	  Huﬀ	  and	  Lynn	  Jorde	  
This	  is	  a	  typical	  Utah	  disease	  pedigree	  
Stephen Guthery, MD 
All	  Clinical	  DiagnosCc	  Tests	  are	  regulated	  in	  America:	  
	  
Clinical	  Laboratory	  Improvement	  Amendments	  




College	  of	  American	  Pathology	  (CAP)	  cerCﬁcaCon	  
Technically,	  CLIA-­‐cerCﬁcaCon	  for	  DNA	  tests	  means	  the	  following:	  
1)  Blood	  drawn	  in	  a	  CLIA-­‐cerCﬁed	  facility	  by	  a	  phlebotomist	  
covered	  by	  that	  facility.	  
2)  DNA	  isolated	  in	  a	  CLIA-­‐cerCﬁed	  facility.	  
3)  Sequencing	  performed	  on	  CLIA-­‐cerCﬁed	  machines	  with	  CLIA-­‐
cerCﬁed	  reagents	  in	  a	  CLIA-­‐cerCﬁed	  facility.	  
4)  Analysis	  performed	  with	  a	  CLIA-­‐cerCﬁed	  bioinformaCcs	  pipeline.	  
5)  DNA	  results	  returned	  to	  paCents	  by	  a	  licensed	  geneCc	  counselor,	  
signed	  oﬀ	  on	  by	  a	  board-­‐cerCﬁed	  medical	  geneCcist.	  
	  
 Any	  clinical	  test	  at	  a	  major	  diagnos6c	  lab	  ﬁrst	  has	  to	  go	  through	  a	  
valida6on	  process	  by	  the	  R&D	  group	  (known	  samples	  are	  run	  through	  
the	  test	  in	  a	  speciﬁc	  way,	  then	  the	  results	  are	  documented	  in	  a	  formal	  
valida6on	  packet	  that	  is	  approved	  by	  management).	  	  All	  results	  are	  
reviewed	  by	  medical	  directors.	  	  
 Axer	  the	  valida6on,	  accoun6ng	  has	  to	  decide	  how	  the	  test	  will	  be	  billed,	  
gene6c	  counselors	  have	  to	  write	  the	  informa6on	  that	  will	  appear	  on	  the	  
clinical	  reports	  and	  the	  test	  has	  to	  be	  formally	  transferred	  into	  the	  
clinical	  lab	  (which	  involves	  puyng	  paperwork	  in	  place,	  geyng	  reagents	  
in	  stock	  and	  training	  employees).	  	  	  
 The	  test	  usually	  also	  has	  to	  be	  integrated	  into	  the	  computer	  system	  and	  
test	  directory,	  although	  some	  of	  this	  can	  be	  bypassed	  if	  one	  requires	  
that	  the	  test	  be	  specially	  ordered.	  	  
 THIS	  TOOK	  ABOUT	  SIX	  MONTHS!!!	  and	  one	  diagnos6c	  lab	  only	  agreed	  to	  




Intersection of variants. We show here the variants identified by 
the three main pipelines as being present in the three males with 
ADHD, but not present in the unaffected mother.   
	  
	  
2-­‐3	  rounds	  of	  sequencing	  at	  BGI	  to	  aIain	  
goal	  of	  >80%	  of	  target	  region	  at	  >20	  reads	  
per	  base	  pair	  
Exome Capture Statistics K24510-84060 K24510-92157-a K24510-84615 K24510-88962 
Target region (bp) 46,401,121  46,401,121  46,401,121  46,257,379  
Raw reads 138,779,950  161,898,170  156,985,870  104,423,704  
Raw data yield (Mb) 12,490  14,571  14,129  9,398  
Reads mapped to genome 110,160,277  135,603,094  135,087,576  83,942,646  
Reads mapped to target region 68,042,793  84,379,239  80,347,146  61,207,116  
Data mapped to target region (Mb) 5,337.69  6,647.18  6,280.01  4,614.47  
Mean depth of target region 115.03 143.25 135.34 99.76 
Coverage of target region (%) 0.9948  0.9947  0.9954  0.9828  
Average read length (bp) 89.91  89.92  89.95  89.75  
Fraction of target covered >=4X 98.17  98.38  98.47  94.25  
Fraction of target covered >=10X 95.18  95.90  95.97  87.90  
Fraction of target covered >=20X 90.12  91.62  91.75  80.70  
Fraction of target covered >=30X 84.98  87.42  87.67  74.69  
Capture specificity (%) 61.52  62.12  59.25  73.16  
Fraction of unique mapped bases on or near target 65.59  65.98  63.69  85.46  
Gender test result M M M F 
Bioinforma6cs	  Analysis	  for	  ADHD	  
pedigree	  
